Multiple Myeloma in 2023 Ways: From Trials to Real Life-Reference-Cited by-同舟云学术

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Published:2023-11-03 Issue:11 Volume:30 Page:9710-9733
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Fazio Manlio¹^ORCID,Del Fabro Vittorio²^ORCID,Parrinello Nunziatina Laura²,Allegra Alessandro³^ORCID,Markovic Uroš²^ORCID,Botta Cirino⁴^ORCID,Accardi Fabrizio⁵,Vincelli Iolanda Donatella⁶,Leotta Salvatore²^ORCID,Elia Federica²,Esposito Benedetta¹,Garibaldi Bruno¹^ORCID,Sapuppo Gabriele¹,Orofino Alessandra¹,Romano Alessandra⁷^ORCID,Palumbo Giuseppe A.⁸^ORCID,Di Raimondo Francesco¹²⁷,Conticello Concetta²^ORCID

Affiliation:

1. Post-Graduation School of Haematology, University of Catania, A.O.U. ‘Policlinico-San Marco’, 95123 Catania, Italy

2. Division of Haematology and BMT, A.O.U. ‘Policlinico-San Marco’, 95123 Catania, Italy

3. Division of Haematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125 Messina, Italy

4. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, 90127 Palermo, Italy

5. Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy

6. Haematology Unit, Haemato-Oncology and Radiotherapy Department, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, Italy

7. Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, Università degli Studi di Catania, 95131 Catania, Italy

8. Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F.Ingrassia”, University of Catania, 95131 Catania, Italy

Abstract

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/30/11/705/pdf

Reference112 articles.

1. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma;Mateos;Leukemia,2022

2. Innovations in treatment and response evaluation in multiple myeloma;Wester;Haematologica,2016

3. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy;Harousseau;J. Clin. Oncol.,2017

4. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol.,2016

5. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry;Takamatsu;Int. J. Hematol.,2019